F. Galeotti
University of Milan
16 Papers
89 Citations
F. Galeotti is an academic researcher from University of Milan. The author has contributed to research in topics: Portal hypertension & Portacaval shunt. The author has an hindex of 6, co-authored 16 publications.
Chat about Author
Papers
Selective distal splenorenal shunt versus side-to-side portacaval shunt. Clinical results of a prospective, controlled study.
Gian Paolo Spina,F. Galeotti,Enrico Opocher,Roberto Santambrogio,G. Cucchiaro,Carmelo Lopez,Giuseppe Pezzuoli +6 more
TL;DR: Data suggest that the selective shunt should be viewed as a first choice strategy in the treatment of portal hypertension and have a less negative effect on postoperative liver function than the portacaval shunt.
34
•Journal Article
Portacaval shunt in the treatment of primary Budd-Chiari syndrome.
TL;DR: The side-to-side portacaval shunt is a reliable and effective procedure for the definitive management of primary budd-Chiari syndrome.
29
Improved quality of life after distal splenorenal shunt. A prospective comparison with side-to-side portacaval shunt.
Giampaolo Spina,Roberto Santambrogio,Enrico Opocher,F. Galeotti,G. Cucchiaro,Mario Strinna,Giuseppe Pezzuoli +6 more
TL;DR: DSRS is associated with a lower global incidence of chronic HE without severe forms and provides a better quality of life than does a nonselective shunt.
14
•Journal Article
Diagnosis of secondary tumors of the pancreas. Analysis of 13 cases
TL;DR: The Authors report their experience of 13 cases of metastatic carcinoma of the pancreas, diagnosed over 350 pancreatic cancers examined by digestive angiography, and affirm that any organ may cause pancreatic metastasis although the kidney and the lung are more frequently the original sites.
14
•Journal Article
The distal splenorenal shunt: an update on experience of 106 cases.
Giuseppe Pezzuoli,G.P. Spina,Roberto Santambrogio,F. Galeotti,Enrico Opocher,G. Cucchiaro,C. Lopez,M. Strinna +7 more
TL;DR: DSRS is effective as treatment of portal hypertension with a low long-term morbidity despite a more troublesome early postoperative period despite a 5-year survival rate of 63%.
8